Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
2상
완료
NCT01939353
| 대상 질환 | Adult ADHD |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 45 명 |
|---|
| 중재(약물) | CTN SR |
|---|
| 시작일 | 2013년 10월 3일 |
|---|
| 완료일 | 2014년 2월 20일 |
|---|
| 결과 공개일 | 2021년 10월 18일 |
|---|
요약
This was a Phase 2 exploratory study to evaluate the efficacy and safety of EB-1020 SR (centanafadine sustained release \[CTN SR\]) in treating participants who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for Attention-Deficit Hyperactivity Disorder (ADHD) on the Mini International Neuropsychiatric Interview Plus, Version 6.0 (M.I.N.I.-Plus). Evaluations included determining an effectiveness signal for ADHD and related symptoms and exploring dosing, tolerability, onset of action, and duration of effect. Dose-response/tolerability relationships with CTN SR were also explored. The 1-week placebo run-in \[single-blind (SB)\] was also used for informal safety comparison purposes.
Change From Baseline-2 in ADHD Symptoms to Week 4 as Assessed by the Adult Attention-Deficit Hyperactivity Disorder Rating Scale (AD HD-RS-IV)
Baseline, Week 4 · score on a scale
| Centanafadine SR 100-500 mg | 38.70 ± 6.19 score on a scale |
|---|
| Centanafadine SR 100-500 mg | -21.41 ± 10.74 score on a scale |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.